GXP Archive | Experts Institut

Tag Archive for: GXP

Continuous manufacturing: future trend in the pharmaceutical industry

The pharmaceutical industry is at a turning point. For decades, traditional batch processes characterized the production of pharmaceuticals. Although these have proven their worth, today they are often considered rigid, slow and resource-intensive. Continuous manufacturing opens up a new path: production no longer takes place in individual batches, but continuously and without interruption. This not only changes the speed of production, but also the quality, flexibility and sustainability of pharmaceutical processes.

What does continuous manufacturing mean?

In contrast to the traditional batch process, continuous manufacturing enables end-to-end production in a closed system. While intermediate storage and waiting times used to be unavoidable, continuous manufacturing allows for constant production and monitoring. As a result, companies benefit from shorter production times, consistent product quality and more efficient use of resources. At the same time, the technology makes it possible to react more flexibly to fluctuations in demand and avoid supply bottlenecks. Continuous manufacturing is therefore much more than a technological innovation; it represents a fundamental paradigm shift in the pharmaceutical industry.

Digitalization as a driver for process stability

The benefits of continuous manufacturing can only be exploited through consistent digital transformation. Modern sensor technology, Process Analytical Technology (PAT) and Advanced Process Control (APC) make it possible to monitor production processes in real time. This ensures process stability and deviations can be detected and corrected immediately. At the same time, end-to-end data acquisition ensures that quality information is seamlessly documented and integrated into regulatory systems. The result is not only stable and safe production, but also greater transparency with regard to GMP compliance.

Focus on regulatory requirements

The authorities have also recognized the potential. The FDA is considered a pioneer and has already granted the first approvals for continuous manufacturing processes. In Europe, the EMA is also taking a closer look at the topic. For companies, this means that investing in continuous manufacturing at an early stage not only makes it easier to obtain approval later on, but also puts them in a strategic position with regard to future inspections. Pilot projects are a valuable way of gaining experience and taking regulatory expectations into account from the outset.

Impact on supply chains and sustainability

An often underestimated aspect of continuous manufacturing is its contribution to sustainability. Reduced energy and material consumption results in less waste. At the same time, continuous production enables production “on demand”, which reduces stock levels and makes medicines available more quickly. Continuous manufacturing therefore offers a decisive advantage, particularly in crisis situations or in the event of supply bottlenecks. For the global supply chains of pharmaceutical companies, this means greater flexibility, shorter response times and overall greater security of supply.

Challenges on the road to implementation

Of course, the switch to continuous manufacturing is associated with hurdles. High initial investments, complex interfaces between IT, automation and quality management as well as the lack of qualified specialists present companies with major challenges. However, this is precisely why it is advisable to proceed step by step: Pilot projects offer the opportunity to minimize risks and build up expertise before the technology is introduced on a large scale. Those who consciously plan this path can actively shape the learning curve and anchor the change in the long term.

Conclusion: Experts Institut as a partner for your transformation

Continuous Manufacturing is not a trend, but the future of pharmaceutical production. Companies that take this step at an early stage not only secure advantages in terms of efficiency and quality, but also with regard to regulatory acceptance and market position.

The Experts Institute supports you with practical advice, tailored training and support for your digitalization and modernization projects. From the feasibility analysis and the development of an implementation plan through to regulatory-compliant implementation, we accompany you on your path to continuous production.

Contact us for customized solutions, together we will make your production future-proof. Get ahead and in touch with us – info@expertsinstitut.de

Read our entire blog: https://experts-institut.de/newsroom/
And feel free to follow us on LinkedIn: https://de.linkedin.com/company/expertsinstitut

24. September 2025/by Christoph Köth

GMP, GXP

GxP audits: How important are they and how are they conducted?

In the highly regulated pharmaceutical industry, audits are more than just a control mechanism – they are an indispensable tool for ensuring the quality and compliance of processes. Audits play a key role in ensuring that companies adhere to the strict requirements of Good Manufacturing Practice (GMP) and other GxP standards. The aim is not only to identify errors, but also to continuously improve processes and eliminate weaknesses before they lead to errors or quality problems. The role of audits in quality management can therefore not be overestimated. They help to meet regulatory requirements and at the same time strengthen the trust of customers and authorities in the company.

Below you will find out what a GxP audit is, why it is so important for companies in regulated industries and how it can be carried out optimally.

What is a GxP audit?

An audit is a systematic, independent and documented review that serves to determine whether activities and results meet the planned requirements. So much for the theory.

In the GxP area, audits are particularly important in practice, as they ensure that all processes actually meet the strict requirements of GMP, GLP and GCP standards. These audits not only check compliance with regulations, but also whether processes are used for continuous improvement and risk reduction and actually make this contribution.

Why are audits in the GxP area so important?

Audits fulfill a central function in the so-called Pharmaceutical Quality System (PQS) and offer many advantages that are important for the entire industry:

Audits guarantee that companies comply with and implement the legal and regulatory requirements in such a way that the medicines produced are of truly impeccable quality and also safe.
Audits make it possible to identify potential errors in operations and production at an early stage so that measures can be taken to minimize risks. This prevents critical errors or weaknesses in the production process from leading to serious problems and questionable medicines from reaching the market and patients.
Audits offer the opportunity to evaluate existing processes and identify optimization potential. In this way, companies can increase their efficiency and improve quality at the same time.
Regular audits strengthen the trust of customers, partners and regulatory authorities. A well-documented and executed audit shows that the company is able to critically scrutinize itself in order to reliably deliver high-quality products to the market.

The audit process: step by step

An audit in the GxP area follows a structured procedure that enables the auditor to thoroughly examine the processes in the company. Typically, an audit consists of six main phases:

Planning: Audit preparation is crucial for success. The parties involved must ensure that all relevant people and documents are available. Thorough planning ensures a smooth process.
The initial meeting: In this step, the auditors and the representatives of the company to be audited meet at the start of the audit. The audit plan or the audit agenda is discussed again. Questions are also clarified here and expectations are defined if they have not already been clearly understood before the audit.
Conducting the audit: The auditor checks the company’s premises, machines, documents and processes. Interviews with employees also take place during this phase in order to assess the practical implementation of the processes.
The final meeting: At the end of the audit, the results are summarized. This is where we discuss what worked well and where there is room for improvement.
The audit report: The auditor prepares a detailed report documenting the results of the audit. This report also contains recommendations to help the company eliminate weaknesses and further improve processes.
Follow-up of the audit results: After the audit, follow-up is essential to ensure that the recommended measures have been implemented. This includes documenting the corrections and, if necessary, rechecks to ensure the sustainability of the improvements.

Preparing the audited company for a GxP audit: how to succeed

Thorough preparation is the key to a successful audit. Companies should ensure that their documents are complete and up-to-date and that their employees are aware of the requirements of the audit. Employee training plays a central role here, as a well-prepared team helps to ensure that the audit runs smoothly and possible deficiencies can be identified at an early stage.

Tips for audit preparation:

Review all important documents, including SOPs (standard operating procedures), batch documentation and qualification documents
If possible, carry out internal mock audits in advance to identify weaknesses in advance
Bring your team up to speed on regulatory requirements and audit expectations

Successful audit practice: the key to success

A successful audit requires careful preparation, a clear structure and detailed follow-up. Cooperation between the auditor and the audited company is of great importance in order to develop a common understanding of the requirements and expectations. This not only promotes compliance, but also the continuous improvement of processes. Companies that integrate regular audits into their business processes improve their quality assurance and reduce the risk of production errors or non-compliance with regulations.

Conclusion: Audits as the key to quality assurance

Audits are an indispensable part of quality management in the GxP sector. They not only help to ensure compliance with regulations, but also promote the quality and safety of products. Thorough preparation and the selection of experienced auditors are crucial to the success of an audit.

At Experts Institut, we not only offer training courses for auditors, but are also happy to support you in ensuring your compliance and continuously improving your processes. We can do “audits”. Contact us at info@expertsinstitut.de

Would you like to find out more?

Listen to our podcast episode “Audits in the pharmaceutical industry”, in which we examine the importance and challenges of audits in detail: https://podcasters.spotify.com/pod/show/experts-insights/episodes/Audits-in-der-Pharmaindustrie-e2of577

Read our blog: experts-institut.de/newsroom

28. October 2024/by Dr. rer. nat. Dietmar Gross

GMP, GXP

Sensible limit values for process capability

The calculation of the process capability in the form of the process capability index (Ppk or Cpk) sets the scatter of the individual results and the position of the mean value in relation to the specification limits. The higher the process capability index, the further away the individual results are from the specification limits.

Calculation of the process capability index:

The following parameters are included in the calculation of the process capability index:

Mean value (μ)
Standard deviation of the mean value (σ)
Upper and lower specification limit (OSG and USG)

The first step is to calculate the process capability indices “Cpo” and “Cpu” for the upper and lower specification limits:

_Cpo = (OSG – μ)/(3σ) OSG = upper specification limit

_Cpu = (μ – USG)/(3σ) USG = lower specification limit

_Cpk = min(_Cpo, _Cpu)

In a second step, the lower value (Cpk = smallest process capability value) of the two values is selected:

The calculation of meaningful Cpk values is only possible from 25 – 30 individual values.

Sample calculation:

Investigated quality characteristic: content of a medicinal product

Specification limits: 95 – 105 mg

Average value: 98 mg

Standard deviation: 0.5 mg

_Cpo = (105 mg – 98 mg)/(3×0.5 mg) = 4.7

_Cpu = (98 mg – 95 mg)/( 3×0.5 mg) = 2.0

_Cpk = min(_Cpo, _Cpu) = 2.0

But what do the Cpk values obtained mean?

Cpk = 1.00

If 1 million units are checked, 2699 faulty units would be found. The distance of the mean value to the next specification limit corresponds to 3 times the standard deviation (3σ) of the values.

Cpk = 1.33

If 1 million units are checked, 66 faulty units would be found. The distance of the mean value to the next specification limit corresponds to 4 times the standard deviation (4σ) of the values.

Cpk = 1.67

If 1 million units are checked, no faulty units would be found. The distance of the mean value to the next specification limit corresponds to 5 times the standard deviation (5σ) of the values.

Cpk = 2.00

If 1 million units are checked, no faulty units would be found. The distance of the mean value to the next specification limit corresponds to 6 times the standard deviation (6σ) of the values.

The limit values selected for the CpK value should be determined on a risk basis. This means that the more critical a quality characteristic is, the higher the acceptance criterion for the CpK value should be.